Precigen, Inc. Stock

Equities

PGEN

US74017N1054

Pharmaceuticals

Real-time Estimate Cboe BZX 03:56:20 2024-04-26 pm EDT 5-day change 1st Jan Change
1.415 USD +1.07% Intraday chart for Precigen, Inc. +6.02% +5.22%
Sales 2024 * 5.59M Sales 2025 * 45.44M Capitalization 348M
Net income 2024 * -89M Net income 2025 * -73M EV / Sales 2024 * 18.4 x
Net cash position 2024 * 246M Net cash position 2025 * 157M EV / Sales 2025 * 4.21 x
P/E ratio 2024 *
-4.16 x
P/E ratio 2025 *
-6.12 x
Employees 202
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.7%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.41%
1 week+6.06%
Current month-3.45%
1 month-0.36%
3 months-1.41%
6 months+29.63%
Current year+4.48%
More quotes
1 week
1.32
Extreme 1.32
1.45
1 month
1.28
Extreme 1.28
1.49
Current year
1.19
Extreme 1.19
1.79
1 year
0.84
Extreme 0.8354
1.88
3 years
0.81
Extreme 0.805
8.72
5 years
0.81
Extreme 0.805
11.10
10 years
0.81
Extreme 0.805
69.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 19-12-31
Director of Finance/CFO 62 21-09-30
Chairman 70 08-01-31
Members of the board TitleAgeSince
Chairman 70 08-01-31
Director/Board Member 68 09-02-28
Corporate Officer/Principal 52 14-07-31
More insiders
Date Price Change Volume
24-04-26 1.41 +0.71% 313 611
24-04-25 1.4 -1.41% 611,778
24-04-24 1.42 +1.43% 568,981
24-04-23 1.4 +1.45% 507,021
24-04-22 1.38 +3.76% 890,547

Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT

More quotes
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.4 USD
Average target price
9 USD
Spread / Average Target
+542.86%
Consensus